MTC8 deficiency

News

Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.

News

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.